Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 22	STN Patent Forums to be held July 19-22, 2004
NEWS 8	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 9	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 10	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 05:51:43 ON 13 JUL 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 05:51:53 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7
DICTIONARY FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.63

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 05:51:58 ON 13 JUL 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 05:58:29 ON 13 JUL 2004
FILE 'REGISTRY' ENTERED AT 05:58:29 ON 13 JUL 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.63

=>
Uploading C:\Examination Auxillary files\09995987\09995987 electd specie.str



chain nodes :
1 2 3 4 5 6 8 9 10 11 12 18 19 20 21 40 41 42 43 44
ring nodes :
7 13 14 15 16 17 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
chain bonds :
1-2 1-44 2-3 2-8 3-4 3-9 3-10 4-5 5-6 5-11 6-7 6-12 15-18 18-19 19-20 19-23 20-21 20-40 21-22 21-43 26-29 36-41 38-42
ring bonds :
7-13 7-17 13-14 14-15 15-16 16-17 22-35 22-39 23-24 23-28 24-25 25-26 26-27 27-28 29-30 29-34 30-31 31-32 32-33 33-34 35-36 36-37 37-38 38-39
exact/norm bonds :
4-5 5-6 6-12 18-19 19-20 19-23 20-21 20-40 21-22 29-30 29-34 30-31 31-32 32-33 33-34
exact bonds :
1-44 2-3 3-4 3-9 3-10 5-11 6-7 15-18 21-43 26-29 36-41 38-42
normalized bonds :
1-2 2-8 7-13 7-17 13-14 14-15 15-16 16-17 22-35 22-39 23-24 23-28 24-25 25-26 26-27 27-28 35-36 36-37 37-38 38-39

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> search l1 exact full
FULL SEARCH INITIATED 05:59:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L2 1 SEA EXA FUL L1

=> d scan

L2 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Propanoic acid, 3-[[4-[[[4-(1-cyclohexen-1-yl)phenyl][[(3,5-dichlorophenyl)amino]carbonyl]amino]methyl]benzoyl]amino]-2,2-difluoro-(9CI)
MF C30 H27 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 52.67 52.88

FILE 'CAPLUS' ENTERED AT 05:59:16 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Jul 2004 VOL 141 ISS 3
FILE LAST UPDATED: 12 Jul 2004 (20040712/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l2
L3 1 L2

=> d l3 ti fbib abs

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of ureidomethylbenzoylaminodifluoropropionates as glucagon antagonists/inverse agonists.
AN 2002:391685 CAPLUS
DN 136:385945
TI Preparation of ureidomethylbenzoylaminodifluoropropionates as glucagon antagonists/inverse agonists.
IN Jorgensen, Anker Steen; Madsen, Peter
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040446	A1	20020523	WO 2001-DK760	20011115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2000-1733	A 20001117
	AU 2002023502	A5	20020527	AU 2002-23502	20011115
				DK 2000-1733	A 20001117
				WO 2001-DK760	W 20011115
	EP 1345891	A1	20030924	EP 2001-996529	20011115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				DK 2000-1733	A 20001117
				WO 2001-DK760	W 20011115
	JP 2004513936	T2	20040513	JP 2002-542774	20011115
				DK 2000-1733	A 20001117
				WO 2001-DK760	W 20011115
	US 2003027849	A1	20030206	US 2001-995987	20011116
				DK 2000-1733	A 20001117
				US 2000-252322P	P 20001120

OS MARPAT 136:385945
AB HO2CCF2CH2NHCOZCHR2N(E)XD [R2 = H, alkyl; Z = (substituted) arylene, heteroarylene; X = (CH2)q(CR12R13)r(CH2)s, CO(CR12R13)r(CH2)s, NR11CO(CR12R13)r(CH2)s, etc.; r = 0, 1; s = 0-3; R11, R12, R13 = H , alkyl; D = (substituted) Ph, naphthyl, pyridyl, indenyl, benzothienyl, thienyl, furyl, benzofuryl, etc.; E = (substituted) cyclohexyl, Ph, PhCH2, PhCH2CH2, indanyl, benzhydryl, etc.], were prepared Thus, Me 4-[(4-cyclohex-1-enylphenylamino)methyl]benzoate (preparation given) in CH2Cl2 containing diisopropylethylamine was treated with 3,5-dichlorophenyl isocyanate to give a residue which was saponified with LiOH. The resulting acid in DMF was treated with 3-[(dimethyliminium)(dimethylamino)methyl]-1,2,3-benzotriazol-1-ium-1-olate hexafluorophosphate,

diisopropylethylamine, Me 3-amino-2,2-difluoropropionate hydrochloride to give the uncharacterized amide ester, which was saponified with aqueous LiOH in THF/MeOH to give 3-[4-[1-(4-cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyl]benzoylamino]-2,2-difluoropropionic acid. In a human glucagon receptor binding assay, title compds. showed IC50<1000 nM.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.94	63.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.74	-0.74

FILE 'REGISTRY' ENTERED AT 06:10:13 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7
DICTIONARY FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Examination Auxillary files\09995987\09995987 first try.str



chain nodes :
1 2 3 4 5 6 8 9 10 11 12 18
ring nodes :
7 13 14 15 16 17
chain bonds :
1-2 1-18 2-3 2-8 3-4 3-9 3-10 4-5 5-6 5-11 6-7 6-12
ring bonds :
7-13 7-17 13-14 14-15 15-16 16-17
exact/norm bonds :

4-5 5-6 6-12
exact bonds :
1-18 2-3 3-4 3-9 3-10 5-11 6-7
normalized bonds :
1-2 2-8 7-13 7-17 13-14 14-15 15-16 16-17

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l4 sss sam
SAMPLE SEARCH INITIATED 06:10:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED 22 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 159 TO 721
PROJECTED ANSWERS: 2 TO 124

L5 2 SEA SSS SAM L4

=> d scan

L5 2 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2H-Pyran-4-propanoic acid, β-(benzoylamino)-α,α-
    difluorotetrahydro- (9CI)
MF C15 H17 F2 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L5 2 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Propanoic acid, 3-[[4-[[[[(3,5-dichlorophenyl)amino]carbonyl][4-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]phenyl]amino]methyl]benzoyl]amino]-2,2-difluoro- (9CI)
MF C34 H35 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> search l4 sss full
FULL SEARCH INITIATED 06:11:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 360 TO ITERATE

100.0% PROCESSED 360 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

L6 6 SEA SSS FUL L4

=> d scan

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclohexanepropanoic acid, β-(benzoylamino)-α,α-difluoro- (9CI)
MF C16 H19 F2 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Furanpropanoic acid, β-(benzoylamino)-α,α-difluoro- (9CI)
MF C14 H11 F2 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2H-Pyran-4-propanoic acid, β-(benzoylamino)-α,α-difluorotetrahydro- (9CI)
MF C15 H17 F2 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Propanoic acid, 3-[[4-[[[4-(1-cyclohexen-1-yl)phenyl][[(3,5-dichlorophenyl)amino]carbonyl]amino]methyl]benzoyl]amino]-2,2-difluoro- (9CI)
MF C30 H27 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Propanoic acid, 3-[[4-[[[[(3,5-dichlorophenyl)amino]carbonyl][4-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]phenyl]amino]methyl]benzoyl]amino]-2,2-difluoro- (9CI)
MF C34 H35 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzenepropanoic acid, β-(benzoylamino)-α,α-difluoro- (9CI)
MF C16 H13 F2 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 155.84 | 219.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION
CA SUBSCRIBER PRICE | 0.00 | -0.74

FILE 'CAPLUS' ENTERED AT 06:11:39 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Jul 2004 VOL 141 ISS 3
FILE LAST UPDATED: 12 Jul 2004 (20040712/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l6
L7 2 L6

=> d his

(FILE 'HOME' ENTERED AT 05:51:43 ON 13 JUL 2004)

FILE 'REGISTRY' ENTERED AT 05:51:53 ON 13 JUL 2004
L1 STRUCTURE UPLOADED
L2 1 SEARCH L1 EXACT FULL

FILE 'CAPLUS' ENTERED AT 05:59:16 ON 13 JUL 2004
L3 1 L2

FILE 'REGISTRY' ENTERED AT 06:10:13 ON 13 JUL 2004
L4 STRUCTURE UPLOADED
L5 2 SEARCH L4 SSS SAM
L6 6 SEARCH L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:11:39 ON 13 JUL 2004
L7 2 L6

=> l7 not l3
L8 1 L7 NOT L3

=> d l8 ti fbib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of taxol derivatives as antitumors
AN 1995:973637 CAPLUS
DN 124:9049

TI Preparation of taxol derivatives as antitumors
IN Terasawa, Hirofumi; Soga, Tsunehiko; Uoto, Koichi
PA Daiichi Seiyaku Co, Japan
SO Jpn. Kokai Tokkyo Koho, 37 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07233159	A2	19950905	JP 1994-314474	19941219
	JP 3400582	B2	20030428		
				JP 1994-314474 A	19941219
				JP 1993-319888	19931220

OS MARPAT 124:9049
GI



I

AB The title compds. [I; X = halo; R1 = protected amino, Z-R6; R6 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; Z = NH, O, CO2, etc.; R2 = (un)substituted alkyl, (un)substituted alkenyl, aryl, etc.; R3 = H, alkyl, halo; R4 = H, protecting group; R5 = H, protecting group] are prepared Thus, a mixture of 7,10-bis(2,2,2-trichloroethoxycarbonyl)-10-deacetylbaccatin III and 3-(tert-butoxycarbonylamino)-2,2-difluoro-3-phenylpropionic acid (preparation given) in toluene containing 4-(dimethylamino)pyridine and di-2-pyridyl carbonate was heated at 80° for 60 h to give I [R1 = tBu-O2C-NH, R2 = Ph, R3 = X = fluoro, R4 = R5 = CO2-CH2-CCl3], which was treated with zinc in HOAc-MeOH at 60° for 15 min to give I [R1 = tBu-O2C-NH, R2 = Ph, R3 = X = fluoro, R4 = R5 = H]. In an in vitro study using P388 tumor cells, this had a GI50 value (concentration inhibiting 50% of tumor cell growth) of 21.0 ng/mL vs. taxol's 30.4 ng/mL.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.97	224.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.74	-1.48

FILE 'REGISTRY' ENTERED AT 06:14:36 ON 13 JUL 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7
DICTIONARY FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Examination Auxillary files\09995987\09995987 second try.str





chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 14
chain bonds :
1-2 1-12 2-3 2-7 3-4 3-8 3-9 4-5 5-6 5-10 6-11 6-14
exact/norm bonds :
4-5 5-6 6-11 6-14
exact bonds :
1-12 2-3 3-4 3-8 3-9 5-10
normalized bonds :
1-2 2-7

G1:C,O,S,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 14:CLASS

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> search l9 sss sam
SAMPLE SEARCH INITIATED 06:15:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 3 TO 163

L10 3 SEA SSS SAM L9

=> d scan

L10 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN D-Valine, N-[N-(5-amino-5-carboxy-1-oxopentyl)-3,3-difluoro-L-α-aspartyl]-, (S)- (9CI)
MF C15 H23 F2 N3 O8



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L10 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Furanpropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α,α-difluoro- (9CI)
MF C12 H15 F2 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Benzofuranpropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α,α-difluoro- (9CI)
MF C16 H17 F2 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>
Uploading C:\Examination Auxillary files\09995987\09995987 second try v.2

L11 STRUCTURE UPLOADED

=> d l11
L11 HAS NO ANSWERS
L11 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> search l11 sss sam
SAMPLE SEARCH INITIATED 06:18:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 2 TO 124

L12 2 SEA SSS SAM L11

=> d scan

L12 2 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2H-Pyran-4-propanoic acid, β-(benzoylamino)-α,α-difluorotetrahydro- (9CI)
MF C15 H17 F2 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 2 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Propanoic acid, 3-[[4-[[[[(3,5-dichlorophenyl)amino]carbonyl][4-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]phenyl]amino]methyl]benzoyl]amino]-2,2-difluoro- (9CI)
MF C34 H35 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> search l11 sss full
FULL SEARCH INITIATED 06:19:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 90 TO ITERATE

100.0% PROCESSED 90 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

L13 6 SEA SSS FUL L11

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	158.36	382.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.48

FILE 'CAPLUS' ENTERED AT 06:19:08 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Jul 2004 VOL 141 ISS 3
FILE LAST UPDATED: 12 Jul 2004 (20040712/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l13
L14 2 L13

=> dhis
L15 18 DHIS

=> d his

(FILE 'HOME' ENTERED AT 05:51:43 ON 13 JUL 2004)

FILE 'REGISTRY' ENTERED AT 05:51:53 ON 13 JUL 2004
L1 STRUCTURE UPLOADED
L2 1 SEARCH L1 EXACT FULL

FILE 'CAPLUS' ENTERED AT 05:59:16 ON 13 JUL 2004
L3 1 L2

FILE 'REGISTRY' ENTERED AT 06:10:13 ON 13 JUL 2004
L4 STRUCTURE UPLOADED
L5 2 SEARCH L4 SSS SAM
L6 6 SEARCH L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:11:39 ON 13 JUL 2004
L7 2 L6
L8 1 L7 NOT L3

```
     FILE 'REGISTRY' ENTERED AT 06:14:36 ON 13 JUL 2004
L9                STRUCTURE UPLOADED
L10             3 SEARCH L9 SSS SAM
L11               STRUCTURE UPLOADED
L12             2 SEARCH L11 SSS SAM
L13             6 SEARCH L11 SSS FULL

     FILE 'CAPLUS' ENTERED AT 06:19:08 ON 13 JUL 2004
L14             2 L13
L15            18 DHIS

=> l154 not 17
L154 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> 114 not 17
L16             0 L14 NOT L7

=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     2.83     385.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.48

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:20:22 ON 13 JUL 2004

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 06:25:34 ON 13 JUL 2004
FILE 'CAPLUS' ENTERED AT 06:25:34 ON 13 JUL 2004
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     2.83     385.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.48

=> d his

     (FILE 'HOME' ENTERED AT 05:51:43 ON 13 JUL 2004)

     FILE 'REGISTRY' ENTERED AT 05:51:53 ON 13 JUL 2004
L1                STRUCTURE UPLOADED
L2              1 SEARCH L1 EXACT FULL

     FILE 'CAPLUS' ENTERED AT 05:59:16 ON 13 JUL 2004
```

```
L3            1 L2

     FILE 'REGISTRY' ENTERED AT 06:10:13 ON 13 JUL 2004
L4              STRUCTURE UPLOADED
L5            2 SEARCH L4 SSS SAM
L6            6 SEARCH L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 06:11:39 ON 13 JUL 2004
L7            2 L6
L8            1 L7 NOT L3

     FILE 'REGISTRY' ENTERED AT 06:14:36 ON 13 JUL 2004
L9              STRUCTURE UPLOADED
L10           3 SEARCH L9 SSS SAM
L11             STRUCTURE UPLOADED
L12           2 SEARCH L11 SSS SAM
L13           6 SEARCH L11 SSS FULL

     FILE 'CAPLUS' ENTERED AT 06:19:08 ON 13 JUL 2004
L14           2 L13
L15          18 DHIS
L16           0 L14 NOT L7

=> file marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    3.29     386.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -1.48

FILE 'MARPAT' ENTERED AT 06:26:03 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 141 ISS 02)(20040709/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US    6740668 25 MAY 2004
DE   10351214 08 APR 2004
EP    1422285 26 MAY 2004
JP 2004149515 27 MAY 2004
WO 2004043951 27 MAY 2004

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> 113
SAMPLE SEARCH INITIATED 06:26:10 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED -   2290 TO ITERATE

 43.7% PROCESSED    1000 ITERATIONS                          15 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.06

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        43271 TO    48329
PROJECTED ANSWERS:             335 TO     1039
```

L17 15 SEA SSS SAM L11

=> d scan

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN
IC ICM C07C229-28
NCL 560041000
CC 30-20 (Terpenes and Terpenoids)
Section cross-reference(s): 34
TI Enzymic reduction method for the preparation of compounds useful for preparing taxanes
ST benzoylphenylisoserine enzymic stereoselective prepn; taxane intermediate benzoylphenylisoserine enzymic prepn; bezoylaminooxophenylpropionate stereoselective redn Hansenula
IT Hansenula polymorpha
(stereoselective preparation of the taxane side chain intermediates by enzymic reduction)
IT Reduction
(enzymic, stereoselective preparation of the taxane side chain intermediates by enzymic reduction)
IT 1605-68-1P, Taxane 33069-62-4P, Taxol
RL: PNU (Preparation, unclassified); PREP (Preparation)
(stereoselective preparation of the taxane side chain intermediates by enzymic reduction)
IT 2835-06-5, DL-Phenylglycine
RL: RCT (Reactant); RACT (Reactant or reagent)
(stereoselective preparation of the taxane side chain intermediates by enzymic reduction)
IT 29670-63-1P, DL-N-Benzoylphenylglycine 153433-79-5P 167095-12-7P 167095-14-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation of the taxane side chain intermediates by enzymic reduction)
IT 153433-80-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective preparation of the taxane side chain intermediates by enzymic reduction)

MSTR 2



G2 = Ak<BD (0-) D (0-) T> (SO (1-) G5)
G5 = F / CO2H
G9 = 186-1 187-185



G10 = Hy (SO (1-) G7)
DER: or salts
MPL: disclosure
STE: as single isomers or mixtures of R and S isomers

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN
IC ICM A61K049-04
NCL 424009451
CC 25-18 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 8, 63
TI Polyiodinated aroyloxy esters useful as contrast agents in x-ray imaging compositions
ST iodinated aroyloxy ester contrast agent; x ray imaging contrast agent iodinated
IT Imaging
(x-ray, contrast agents, polyiodinated aroyloxy esters useful as contrast agents in x-ray imaging compns.)
IT 737-31-5, Sodium diatrizoate 14660-52-7, Ethyl 5-bromovalerate 25542-62-5, Ethyl 6-bromohexanoate
RL: RCT (Reactant); RACT (Reactant or reagent)
(polyiodinated aroyloxy esters useful as contrast agents in x-ray imaging compns.)
IT 156644-63-2P, Win 68061 156946-45-1P, Win 67722 156971-69-6P, Win 68136 156971-70-9P, Win 67954 156971-71-0P, Win 67995 156971-72-1P, Win 68039 156971-74-3P, Win 68166 156971-75-4P, Win 68767 156971-76-5P, Win 68888 156971-77-6P, Win 68384 156971-78-7P, Win 68038 156971-79-8P, Win 69732 173993-95-8P, Win 68060 173993-96-9P, Win 70467 173993-97-0P, Win 71300 173993-98-1P, Win 72313 173994-07-5P, Win 69943 173994-08-6P, Win 69944 173994-09-7P, Win 69979 174024-56-7P, Win 22256
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(x-ray imaging contrast agent; polyiodinated aroyloxy esters useful as contrast agents in x-ray imaging compns.)

MSTR 2

G5 = alkylene<EC (5-21) C, DC (0) M3> (SO (1-) G7)
G7 = F / 41



G8 = Hy<EC (1-) N, AN (1) N, RC (1), RS (1) M4 (1) X7>
G9 = NH
MPL: claim 9

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN
IC ICM C08K005-098
ICS C08K005-12; C08K005-15; C08L023-02
CC 37-6 (Plastics Manufacture and Processing)
Section cross-reference(s): 24
TI Manufacture of crystal nucleating agents for polyolefins, and polyolefin compositions
ST polyolefin crystal nucleation agent manuf; bicyclooctenedicarboxylic anhydride methanolysis sapon polyolefin nucleation; bicyclooctenedicarboxylate ester salt manuf polyolefin nucleation
IT Crystal nucleating agents

(manufacture of crystal nucleating agents for polyolefins)
IT Polyolefins
RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)
(manufacture of crystal nucleating agents for polyolefins)
IT 124-30-1, Octadecylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of norbornenedicarboxylic anhydride; manufacture of crystal nucleating agents for polyolefins)
IT 1200-88-0P 23838-82-6P, Bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid disodium salt 126809-55-0P 210362-60-0P 210362-61-1P 210362-62-2P 210362-63-3P 210362-64-4P
RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)
(manufacture of crystal nucleating agents for polyolefins)
IT 465-48-5 210362-65-5 210362-66-6 210362-67-7 210362-68-8
RL: MOA (Modifier or additive use); USES (Uses)
(manufacture of crystal nucleating agents for polyolefins)
IT 9003-07-0, Polypropylene
RL: MSC (Miscellaneous)
(manufacture of crystal nucleating agents for polyolefins)
IT 9010-79-1, Petrothene PP 8310GO
RL: PRP (Properties)
(manufacture of crystal nucleating agents for polyolefins)
IT 6708-37-8, Bicyclo[2.2.2]oct-5-ene-2,3-dicarboxylic anhydride
RL: RCT (Reactant); RACT (Reactant or reagent)
(methanolysis and partial saponification; manufacture of crystal nucleating agents for polyolefins)
IT 826-62-0, Norborn-5-ene-2,3-dicarboxylic anhydride
RL: RCT (Reactant); RACT (Reactant or reagent)
(methanolysis; manufacture of crystal nucleating agents for polyolefins)
IT 5826-73-3P, Bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid dimethyl ester 31517-37-0P, Bicyclo[2.2.2]oct-5-ene-2,3-dicarboxylic acid dimethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and partial saponification; manufacture of crystal nucleating agents for polyolefins)
IT 3813-52-3, Norborn-5-ene-2,3-dicarboxylic acid 34487-58-6, Bicyclo[2.2.2]oct-5-ene-2,3-dicarboxylic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(salification with LiOH; manufacture of crystal nucleating agents for polyolefins)
IT 142186-01-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(saponification; manufacture of crystal nucleating agents for polyolefins)

MSTR 1



G1 = Ak<EC (1-18) C, BD (0-) D (0) T>

G2 = 9



G3 = 12



G4 = alkyl<(1-18)> (SO (1-) G5)
G5 = X / CO2H
G8 = 17-1 18-3



G9 = O
G14 = Ak<EC (1-18) C, BD (0-) D (0) T>
DER: or salts
MPL: claim 1

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN
IC ICM C07D239-94
ICS A61K031-505; A61P035-00
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases
ST bicyclic amine deriv prepn tyrosine kinase inhibitor; quinazolinylbenzenesulfonamide prepn tyrosine kinase inhibitor
IT Antiarteriosclerotics
(antiatherosclerotics; preparation of bicyclic amine derivs. as inhibitors of class 1 receptor tyrosine kinases)
IT Antitumor agents
Fibrosis
Psoriasis
(preparation of bicyclic amine derivs. as inhibitors of class 1 receptor tyrosine kinases)
IT Artery, disease
(restenosis; preparation of bicyclic amine derivs. as inhibitors of class 1 receptor tyrosine kinases)
IT 364038-72-2P 364038-73-3P 364038-74-4P 364038-75-5P 364038-76-6P
364038-77-7P 364038-78-8P 364038-79-9P 364038-80-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic amine derivs. as inhibitors of class 1 receptor tyrosine kinases)
IT 141436-78-4, Protein kinase c
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of bicyclic amine derivs. as inhibitors of class 1 receptor tyrosine kinases)
IT 70-55-3, 4-Methylbenzenesulfonamide 98-64-6, 4-Chlorobenzenesulfonamide 701-34-8, 4-Bromobenzenesulfonamide: 1129-26-6, 4-Methoxybenzenesulfonamide 6961-82-6, 2-Chlorobenzenesulfonamide:

13790-39-1, 4-Chloro-6,7-dimethoxyquinazoline 17260-71-8, 3-Chlorobenzenesulfonamide 53730-99-7, 2-Iodobenzenesulfonamide 73542-86-6, 2-Cyanobenzenesulfonamide 92748-09-9, 2-Bromobenzenesulfonamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of bicyclic amine derivs. as inhibitors of class 1 receptor tyrosine kinases)

MSTR 1



G8 = Ak<EC (1-6) C, BD (0-) D (0-) T> (SO (1-3) G9)
G9 = F / CO2H (SO) / 141



G10 = heteroaryl
MPL: claim 1
NTE: or salts, solvates, hydrates, and N-oxides

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN
IC ICM C07D239-91
ICS C07D495-04; C07D513-04; A61K031-519; A61P003-04
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
TI Preparation of pyrimidinones as melanin concentrating hormone receptor 1 antagonists
ST pyrimidinone prepn melanin concg hormone receptor 1 antagonist
IT Antiarteriosclerotics
Antihypertensives
(combined with pyrimidinone melanin-concentrating hormone receptor 1 antagonists)
IT Mental disorder
(depression; preparation of pyrimidinones as melanin-concentrating hormone receptor
1 antagonists)
IT Hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanin concentrating hormone receptor 1, antagonists; preparation of pyrimidinones as melanin-concentrating hormone receptor 1 antagonists)
IT Antidepressants
Antidiabetic agents
Antiobesity agents
Anxiety
Anxiolytics
Diabetes mellitus
Human
Obesity
(preparation of pyrimidinones as melanin-concentrating hormone receptor 1 antagonists)
IT 515141-24-9P, 3-[4-(2-Aminoethoxy)-3-methoxyphenyl]-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one trifluoroacetate

515141-28-3P, 6-(4-Chlorophenyl)-3-[4-[2-[(4-isopropylbenzyl)amino]ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-51-2P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-75-0P, 3-[3-Methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-7-[4-(trifluoromethyl)phenyl]-4(3H)-quinazolinone 515141-99-8P, 6-(4-Chlorophenyl)-3-[4-[((2S,4R)-4-hydroxypyrrolidin-2-yl)methoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-03-7P, 6-(4-Chlorophenyl)-3-[4-[((2S,4S)-4-fluoropyrrolidin-2-yl)methoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-26-4P, N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenyl]-4-methylbenzenesulfonamide 515142-27-5P, N-(3-Bromopropyl)-N-[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenyl]-4-methylbenzenesulfonamide 515142-32-2P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[(2-(pyrrolidin-1-yl)ethyl)amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-56-0P, 6-(4-Chlorophenyl)-3-[4-[[2-(dimethylamino)ethyl]amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-64-0P, 6-(4-Chlorophenyl)-3-[4-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrimidinones as melanin-concentrating hormone
receptor 1 antagonists)

IT 515141-02-3P, 3-[3-Methoxy-4-[2-(1-piperidinyl)ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-07-8P, 3-[3-Methoxy-4-[2-(4-phenyl-1-piperidinyl)ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-08-9P, 3-[3-Methoxy-4-[2-[methyl(propyl)amino]ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-09-0P, 3-[4-[2-[Ethyl(methyl)amino]ethoxy]-3-methoxyphenyl]-7-phenyl-4(3H)-quinazolinone 515141-10-3P, 3-[4-[2-(1-Azepanyl)ethoxy]-3-methoxyphenyl]-7-phenyl-4(3H)-quinazolinone 515141-11-4P, 3-[4-[2-[4-(4-Chlorophenyl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]-7-phenyl-4(3H)-quinazolinone 515141-12-5P, 3-[4-[2-[Cyclohexyl(methyl)amino]ethoxy]-3-methoxyphenyl]-7-phenyl-4(3H)-quinazolinone 515141-13-6P, 3-[3-Methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-14-7P, 3-[3-Methoxy-4-[2-[methyl(2-phenylethyl)amino]ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-15-8P, 3-[4-[2-[Benzyl(methyl)amino]ethoxy]-3-methoxyphenyl]-7-(4-fluorophenyl)-4(3H)-quinazolinone 515141-17-0P, 3-[4-[2-(Dimethylamino)ethoxy]-3-methoxyphenyl]-7-(4-fluorophenyl)-4(3H)-quinazolinone 515141-18-1P, 3-[4-[2-[Benzyl(methyl)amino]ethoxy]-3-methoxyphenyl]-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-20-5P, 6-(4-Chlorophenyl)-3-[4-[2-(dimethylamino)ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-21-6P, 6-(4-Chlorophenyl)-3-[4-[2-[ethyl(methyl)amino]ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-22-7P, 6-(4-Chlorophenyl)-3-[4-[2-(diethylamino)ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-29-4P, 6-(4-Chlorophenyl)-3-[4-[2-[(4-isopropylbenzyl)(methyl)amino]ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-30-7P, 3-[4-[2-[(4-Chlorobenzyl)amino]ethoxy]-3-methoxyphenyl]-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-31-8P, 3-[4-[2-[(4-Chlorobenzyl)(methyl)amino]ethoxy]-3-methoxyphenyl]-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-32-9P, 6-(4-Chlorophenyl)-3-[4-[2-[(4-fluorobenzyl)amino]ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-33-0P, 6-(4-Chlorophenyl)-3-[4-[2-[(4-fluorobenzyl)(methyl)amino]ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-34-1P, 4-[[[2-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenoxy]ethyl]amino]methyl]benzonitrile 515141-35-2P, 4-[[[2-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-

methoxyphenoxy]ethyl](methyl)amino]methyl]benzonitrile 515141-36-3P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[2-(N-methylanilino)ethoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-38-5P, 6-(4-Chlorophenyl)-3-[4-[2-(N-ethyl-3-methylanilino)ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-39-6P, 4-[[2-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenoxy]ethyl](methyl)amino]benzonitrile 515141-41-0P, 3-[4-[2-[4-Chloro-N-methylanilino]ethoxy]-3-methoxyphenyl]-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-43-2P, 3-[4-[((2S)-2-Aminopropyl)oxy]-3-methoxyphenyl]-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-45-4P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-47-6P, 3-[3-Methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-6-phenylthieno[3,2-d]pyrimidin-4(3H)-one 515141-50-1P, 6-(4-Fluorophenyl)-3-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-53-4P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one maleate 515141-54-5P, 6-(4-Methoxyphenyl)-3-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-55-6P, 2-(4-Chlorophenyl)-6-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-[1,3]thiazolo[4,5-d]pyrimidin-7(6H)-one 515141-57-8P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-(2-methyl-2-(pyrrolidin-1-yl)propoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-64-7P, 6-(4-Chlorophenyl)-3-[4-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-70-5P, 6-(4-Chlorophenyl)-3-[4-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-83-0P, 7-(4-Fluoro-3-methylphenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515141-85-2P, 3-[3-Methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-7-(4-methylphenyl)-4(3H)-quinazolinone 515141-87-4P, 7-(4-Methoxyphenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515141-89-6P, 7-(4-Chlorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515141-91-0P, 7-(3-Chlorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone maleate 515141-92-1P, 7-(4-Ethylphenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515141-93-2P, 7-(4-Fluorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515141-95-4P, 7-(3-Chloro-4-fluorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone maleate 515141-96-5P, 7-(3-Fluorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515141-97-6P, 3-[3-Chloro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-98-7P, 3-[3-Chloro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-7-(4-fluorophenyl)-4(3H)-quinazolinone 515142-02-6P, 6-(4-Chlorophenyl)-3-[4-[((2S,4R)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-05-9P, 6-(4-Chlorophenyl)-3-[4-[((2S,4S)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one maleate 515142-06-0P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-07-1P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[(1-methyl-3-piperidinyl)methoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-08-2P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]amino]ethoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-10-6P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-(3-(pyrrolidin-1-yl)propoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-13-9P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-(3-(piperidin-1-yl)propoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-14-0P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-(3-morpholin-4-ylpropoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-15-1P, 6-(4-Chlorophenyl)-3-[4-[3-(cyclopropylamino)propoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-16-2P, 6-(4-Chlorophenyl)-3-[4-[3-(cyclobutylamino)propoxy]-3-

methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-17-3P,
6-(4-Chlorophenyl)-3-[4-[3-(cyclopentylamino)propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-18-4P,
6-(4-Chlorophenyl)-3-[4-[3-(cyclohexylamino)propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-19-5P,
6-(4-Chlorophenyl)-3-[4-[3-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy]-
3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-20-8P,
6-(4-Chlorophenyl)-3-[4-[3-(dimethylamino)propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-21-9P,
6-(4-Chlorophenyl)-3-[4-[3-(diethylamino)propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-22-0P,
3-[4-[3-[Benzyl(methyl)amino]propoxy]-3-methoxyphenyl]-6-(4-
chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515142-23-1P,
6-(4-Chlorophenyl)-3-[4-[3-((3R)-3-hydroxypyrrolidin-1-yl)propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-24-2P,
N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-
methoxyphenyl]-2-(pyrrolidin-1-yl)acetamide 515142-28-6P,
N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-
methoxyphenyl]-N-[3-(dimethylamino)propyl]-4-methylbenzenesulfonamide
515142-29-7P, N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-
yl]-2-methoxyphenyl]-N-[3-(diethylamino)propyl]-4-methylbenzenesulfonamide
515142-30-0P, N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-
yl]-2-methoxyphenyl]-4-methyl-N-(3-(piperidin-1-
yl)propyl)benzenesulfonamide 515142-31-1P, N-[4-[6-(4-Chlorophenyl)-4-
oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenyl]-4-methyl-N-(3-
(pyrrolidin-1-yl)propyl)benzenesulfonamide 515142-34-4P,
N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-
methoxyphenyl]-2,2,2-trifluoro-N-(2-(pyrrolidin-1-yl)ethyl)acetamide
515142-35-5P, N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-
yl]-2-methoxyphenyl]-N-(2-(pyrrolidin-1-yl)ethyl)-2-furamide
515142-36-6P, N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-
yl]-2-methoxyphenyl]-N-(2-(pyrrolidin-1-yl)ethyl)acetamide 515142-37-7P,
4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-
methoxyphenyl(2-(pyrrolidin-1-yl)ethyl)formamide 515142-38-8P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[methyl(2-(pyrrolidin-1-
yl)ethyl)amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-39-9P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[((2S)-1-methylpyrrolidin-2-
yl)methoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-41-3P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[2-(1-methylpyrrolidin-2-
yl)ethoxy]phenyl]thieno[3,2-d]pyrimidin-4-(3H)-one 515142-43-5P,
6-(4-Chlorophenyl)-3-[4-[2-((3R)-3-hydroxypyrrolidin-1-yl)ethoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-47-9P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-2-
methylthieno[3,2-d]pyrimidin-4(3H)-one acetate 515142-48-0P,
3-[4-[[2-(Diethylamino)ethyl]amino]-3-methoxyphenyl]-6-(4-
fluorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515142-49-1P,
6-(4-Fluorophenyl)-3-[3-methoxy-4-(4-methylpiperazin-1-
yl)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-50-4P,
6-(4-Fluorophenyl)-3-[3-methoxy-4-[[3-(2-oxopyrrolidin-1-
yl)propyl]amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-51-5P,
6-(4-Fluorophenyl)-3-[3-methoxy-4-[(2-(piperidin-1-
yl)ethyl)amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-52-6P,
3-[3-Methoxy-4-[((2R)-1-methylpyrrolidin-2-yl)methoxy]phenyl]-6-
phenylthieno[3,2-d]pyrimidin-4(3H)-one 515142-53-7P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[((2R)-pyrrolidin-2-
ylmethyl)amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-54-8P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[((2S)-pyrrolidin-2-
ylmethyl)amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-55-9P,
6-(4-Fluorophenyl)-3-[3-methoxy-4-[((2R)-1-methylpyrrolidin-2-
yl)methoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-57-1P,
6-(4-Chlorophenyl)-3-[4-[[2-(dimethylamino)ethyl](methyl)amino]phenyl]thie
no[3,2-d]pyrimidin-4(3H)-one hydrochloride 515142-58-2P,
6-(4-Chlorophenyl)-3-[4-[[2-(1-pyrrolidinyl)ethyl]amino]phenyl]thieno[3,2-

d]pyrimidin-4(3H)-one 515142-59-3P, 6-(4-Chlorophenyl)-3-[4-[[2-(4-morpholinyl)ethyl]amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-60-6P, 6-(4-Chlorophenyl)-3-[4-(4-methyl-1-piperazinyl)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-61-7P, 6-(4-Chlorophenyl)-3-[4-[[2-(diethylamino)ethyl]sulfanyl]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-63-9P, 6-(4-Chlorophenyl)-3-[4-[[2-(4-morpholinyl)ethyl]sulfanyl]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-67-3P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[2-(3-oxopyrrolidin-1-yl)ethoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-69-5P, 6-(4-Chlorophenyl)-3-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one trifluoroacetate 515142-70-8P, 6-(4-Chlorophenyl)-3-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-71-9P, 6-(4-Fluorophenyl)-3-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one hydrochloride 515142-72-0P, 5-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-(2-(pyrrolidin-1-yl)ethoxy)benzonitrile hydrochloride 515142-73-1P, 5-[6-(4-Fluorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-(2-(pyrrolidin-1-yl)ethoxy)benzonitrile hydrochloride 515142-74-2P, 6-(4-Chlorophenyl)-3-[3-fluoro-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrimidinones as melanin-concentrating hormone receptor 1 antagonists)

IT 98-80-6, Phenylboronic acid 103-67-3, N-Methyl-N-benzylamine 109-64-8, 1,3-Dibromopropane 110-89-4, Piperidine, reactions 122-03-2, 4-Isopropylbenzaldehyde 123-75-1, Pyrrolidine, reactions 350-46-9, 4-Nitrofluorobenzene 600-00-0, Ethyl 2-bromo-2-methylpropanoate 621-63-6, 2,2-Diethoxyethanol 869-24-9, 2-(Diethylamino)ethyl chloride hydrochloride 1009-36-5, 2-Chloro-5-nitroanisole 1193-02-8, 4-Aminothiophenol 2365-48-2, Methyl thioglycolate 2799-21-5, (3R)-Pyrrolidin-3-ol 2955-88-6, 1-(2-Hydroxyethyl)pyrrolidine 3251-56-7, 4-Nitroguaiacol 3619-22-5, 4-Methylbenzohydrazide 4637-24-5, Dimethylformamide dimethyl acetal 5307-02-8, 2-Methoxybenzene-1,4-diamine 5990-17-0, Methyl 4-chlorobenzenecarbodithioate 6280-88-2, 2-Nitro-4-chlorobenzoic acid 7154-73-6, 2-(Pyrrolidin-1-yl)ethanamine 22564-43-8, N-(2-Chloroethyl)-N-ethyl-3-methylaniline 26690-80-2, tert-Butyl 2-hydroxyethylcarbamate 34381-71-0, ((2S)-1-Methylpyrrolidin-2-yl)methanol 40499-83-0, 3-Pyrrolidinol 41995-04-4, 4-Chloro-2-nitrobenzoyl chloride 50609-01-3, 4-(2-(Pyrrolidin-1-yl)ethoxy)aniline 52694-50-5, 3-(Chloromethyl)-1-methylpiperidine 84765-24-2, (2S)-2-[(tert-Butoxycarbonyl)amino]propyl p-toluenesulfonate 84877-52-1, 2-(N-Methylanilino)ethyl p-toluenesulfonate 89283-22-7, 5-Bromo-3-nitrothiophene-2-carboxaldehyde 91076-93-6, Methyl 3-amino-5-(4-chlorophenyl)thiophene-2-carboxylate 116574-74-4, 3-Fluoropyrrolidine 128796-39-4, 4-Trifluoromethylphenylboronic acid 164029-28-1, 4-(4-Nitro-2-methoxyphenoxy)-1-methylpiperidine 203866-16-4, 1-tert-Butyl 2-methyl (2S,4S)-4-fluoro-1,2-pyrrolidinedicarboxylate 316131-01-8, 3,3-Difluoropyrrolidine 394248-90-9, 3-Methoxy-4-[2-(1-pyrrolidinyl)ethoxy]aniline 515141-40-9, 2-[4-Cyano-N-methylanilino]ethyl p-toluenesulfonate 515141-42-1, 2-[4-Chloro-N-methylanilino]ethyl p-toluenesulfonate 515142-00-4, tert-Butyl (2S,4R)-2-[(4-amino-2-methoxyphenoxy)methyl]-4-hydroxypyrrolidine-1-carboxylate
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidinones as melanin-concentrating hormone receptor 1 antagonists)

IT 2506-46-9P, 1-(2-Bromoethoxy)-2-methoxy-4-nitrobenzene 32515-32-5P, Ethyl 2-methyl-2-(pyrrolidin-1-yl)propanoate 40179-35-9P,

4-[[2-(Diethylamino)ethyl]sulfanyl]aniline 101079-64-5P, 5-Bromo-3-nitrothiophene-2-carboxylic acid 101258-96-2P, 2-Methyl-2-(pyrrolidin-1-yl)propan-1-ol 265654-77-1P, 1-[2-(4-Nitrophenoxy)ethyl]pyrrolidine 317356-27-7P, tert-Butyl (2S,4S)-4-fluoro-2-(hydroxymethyl)-1-pyrrolidinecarboxylate 476415-09-5P, tert-Butyl (2S,4S)-4-fluoro-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-1-pyrrolidinecarboxylate 515141-03-4P, 4-(2,2-Diethoxyethoxy)-3-methoxyaniline 515141-04-5P, 4-Chloro-N-[4-(2,2-diethoxyethoxy)-3-methoxyphenyl]-2-nitrobenzamide 515141-05-6P, 7-Chloro-3-[4-(2,2-diethoxyethoxy)-3-methoxyphenyl]-4(3H)-quinazolinone 515141-06-7P, 3-[4-(2,2-Diethoxyethoxy)-3-methoxyphenyl]-7-phenyl-4(3H)-quinazolinone 515141-16-9P, 3-[4-(2,2-Diethoxyethoxy)-3-methoxyphenyl]-7-(4-fluorophenyl)-4(3H)-quinazolinone 515141-19-2P, 6-(4-Chlorophenyl)-3-[4-(2,2-diethoxyethoxy)-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-25-0P, tert-Butyl 2-(2-methoxy-4-nitrophenoxy)ethylcarbamate 515141-26-1P, tert-Butyl 2-(4-amino-2-methoxyphenoxy)ethylcarbamate 515141-27-2P, tert-Butyl 2-[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenoxy]ethylcarbamate 515141-37-4P, 6-(4-Chlorophenyl)-3-(4-hydroxy-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-44-3P, tert-Butyl (1S)-2-[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenoxy]-1-methylethylcarbamate 515141-46-5P, 3-Methoxy-4-[(1-methyl-4-piperidinyl)oxy]aniline 515141-48-7P, 5-Bromo-N-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-3-nitrothiophene-2-carboxamide 515141-49-8P, 6-Bromo-3-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-52-3P, Methyl 5-(4-chlorophenyl)-3-[[(E)-(dimethylamino)methylidene]amino]-2-thiophenecarboxylate 515141-56-7P, Methyl 4-amino-2-(4-chlorophenyl)-1,3-thiazole-5-carboxylate 515141-59-0P, 1-[2-(2-Methoxy-4-nitrophenoxy)-1,1-dimethylethyl]pyrrolidine 515141-62-5P, 3-Methoxy-4-(2-methyl-2-(pyrrolidin-1-yl)propoxy)aniline 515141-66-9P, 3,3-Difluoro-1-[2-(2-methoxy-4-nitrophenoxy)ethyl]pyrrolidine 515141-68-1P, 4-[2-(3,3-Difluoropyrrolidin-1-yl)ethoxy]-3-methoxyaniline 515141-72-7P, 3-Fluoro-1-[2-(2-methoxy-4-nitrophenoxy)ethyl]pyrrolidine 515141-77-2P, 4-Chloro-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-nitrobenzamide 515141-79-4P, 2-Amino-4-chloro-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzamide 515141-81-8P, 7-Chloro-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515142-01-5P, tert-Butyl (2S,4R)-2-[[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenoxy]methyl]-4-hydroxypyrrolidine-1-carboxylate 515142-09-3P, 6-(4-Chlorophenyl)-3-[4-(2-isothiocyanatoethoxy)-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-11-7P, Methyl 5-(4-chlorophenyl)-3-[[(1Z)-(dimethylamino)methylidene]amino]thiophene-2-carboxylate 515142-12-8P, 3-[4-(3-Bromopropoxy)-3-methoxyphenyl]-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515142-25-3P, 3-(4-Amino-3-methoxyphenyl)-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515142-33-3P, 2-Methoxy-4-nitro-N-(2-(pyrrolidin-1-yl)ethyl)aniline 515142-40-2P, (2S)-2-[(2-Methoxy-4-nitrophenoxy)methyl]-1-methylpyrrolidine 515142-42-4P, 2-[2-(2-Methoxy-4-nitrophenoxy)ethyl]-1-methylpyrrolidine 515142-44-6P, (3R)-1-[2-(2-Methoxy-4-nitrophenoxy)ethyl]pyrrolidin-3-ol 515142-45-7P, 3-Amino-5-(4-chlorophenyl)-N-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thiophene-2-carboxamide 515142-62-8P, Methyl 5-(4-chlorophenyl)-3-[[(dimethylamino)methylidene]amino]-2-thiophenecarboxylate 515142-65-1P, 1-[2-(2-Methoxy-4-nitrophenoxy)ethyl]pyrrolidin-3-ol 515142-66-2P, 1-[2-(4-Amino-2-methoxyphenoxy)ethyl]pyrrolidin-3-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidinones as melanin-concentrating hormone receptor 1 antagonists)

MSTR 5

H———G18

G18 = 77



G20 = Ph / OH / F
G21 = Ak<EC (1-6) C, BD (ALL) SE> (SO (1-) G20)
MPL: claim 34
NTE: substitution is restricted

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN
IC ICM C07D495-04
ICS A61K031-519; A61P009-10
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
TI Preparation of pyrimidone and pyridone compounds as Lp-PLA2 inhibitors for treating atherosclerosis
ST pyrimidone pyridone heterocyclyl fused prepn lipoprotein phospholipase A2 inhibitor; atherosclerosis pyrimidone pyridone heterocyclyl fused thienopyrimidinone prepn
IT Antiarteriosclerotics
(antiatherosclerotics; preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)
IT Atherosclerosis
Human
(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)
IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)
IT 9001-84-7, Phospholipase A2 76901-00-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)
IT 528840-56-4P 528840-57-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)
IT 105-36-2, Ethyl bromoacetate 2689-68-1, Methyl 4-oxotetrahydrothienyl-3-carboxylate 304694-40-4, N-(2-Diethylaminoethyl)-4-(4-trifluoromethylphenyl)benzylamine 412961-31-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)
IT 528840-58-6P, 2-[2-(2,3-Difluorophenyl)ethyl]-5,7-dihydro-1H-thieno[3,4-d]pyrimidin-4-one 528840-59-7P, Ethyl [2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-5,7-dihydro-4H-thieno[3,4-d]pyrimidin-1-yl]acetate 528840-60-0P, [2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-5,7-dihydro-4H-thieno[3,4-d]pyrimidin-1-yl]acetic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for

treating atherosclerosis)

MSTR 1



G5 = alkylamino<(1-12)> / Hy<EC (5-7) A (1-) N (0-) O (0-) S (0) OTHERQ, AN (1-) N> (SO)
G19 = F / 68

C(O)-G5
68

G32 = alkyl<(1-6)> (SO (1-3) G19)
MPL: claim 1
NTE: and pharmaceutically acceptable salts

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.26	387.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.48

FILE 'CAPLUS' ENTERED AT 06:27:54 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Jul 2004 VOL 141 ISS 3
FILE LAST UPDATED: 12 Jul 2004 (20040712/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d his

     (FILE 'HOME' ENTERED AT 05:51:43 ON 13 JUL 2004)

     FILE 'REGISTRY' ENTERED AT 05:51:53 ON 13 JUL 2004
L1                STRUCTURE UPLOADED
L2              1 SEARCH L1 EXACT FULL

     FILE 'CAPLUS' ENTERED AT 05:59:16 ON 13 JUL 2004
L3              1 L2

     FILE 'REGISTRY' ENTERED AT 06:10:13 ON 13 JUL 2004
L4                STRUCTURE UPLOADED
L5              2 SEARCH L4 SSS SAM
L6              6 SEARCH L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 06:11:39 ON 13 JUL 2004
L7              2 L6
L8              1 L7 NOT L3

     FILE 'REGISTRY' ENTERED AT 06:14:36 ON 13 JUL 2004
L9                STRUCTURE UPLOADED
L10             3 SEARCH L9 SSS SAM
L11               STRUCTURE UPLOADED
L12             2 SEARCH L11 SSS SAM
L13             6 SEARCH L11 SSS FULL

     FILE 'CAPLUS' ENTERED AT 06:19:08 ON 13 JUL 2004
L14             2 L13
L15            18 DHIS
L16             0 L14 NOT L7

     FILE 'MARPAT' ENTERED AT 06:26:03 ON 13 JUL 2004
L17            15 L13

     FILE 'CAPLUS' ENTERED AT 06:27:54 ON 13 JUL 2004

=> l17
L18           15 L17

=> d l18 1-15 ti

L18  ANSWER 1 OF 15  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Process for the preparation of thieno[3,2-b]pyrrole derivatives

L18  ANSWER 2 OF 15  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Preparation of pyrimidone and pyridone compounds as Lp-PLA2 inhibitors for
     treating atherosclerosis

L18  ANSWER 3 OF 15  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Synthesis of diazabicycloalkanecarboxamides as caspase inhibitors

L18  ANSWER 4 OF 15  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Preparation of pyrimidinones as melanin concentrating hormone receptor 1
     antagonists

L18  ANSWER 5 OF 15  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Androgen receptor modulators and methods of use thereof

L18  ANSWER 6 OF 15  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Preparation of bicyclic amine derivatives as inhibitors of class 1
```

receptor tyrosine kinases

L18 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Benzopyrrolone derivatives and related compds. as inhibitors of c-jun n-terminal kinases (JNK)

L18 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Manufacture of crystal nucleating agents for polyolefins, and polyolefin compositions

L18 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of amino acid heterobicyclic amide derivatives as farnesyl transferase inhibitors

L18 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Polyiodinated aroyloxy esters useful as contrast agents in x-ray imaging compositions

L18 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of phenylimidazolidines as antiandrogenics

L18 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Enzymic reduction method for the preparation of compounds useful for preparing taxanes

L18 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Light-sensitive color photographic elements and process for developing them.

L18 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Heterocyclic HIV retroviral protease inhibitors

L18 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of 4-nitrophenyl-1,4-dihydropyridamides as cardiovascular agents

=> logoff hols
'HOLS' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.39	397.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.48

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:35:04 ON 13 JUL 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD: